and pathologic processes such as embryogenesis, wound healing, inflammation and tumor progression. The function of fibronectin in regulating normal cell adhesion and migration is well documented, but its function in cancer progression is only partially unraveled. We have reported previously that fibronectin stimulates the proliferation and survival of non-small lung carcinoma cells through upregulation of pro-oncogenic signals related to cyclooxygenase-2/ phosphatidylinositol-3-kinase/protein kinase B (COX-2/PI3-K/ AKT)/mammalian target of rapamycin triggered by activation of the integrin α5β1. Here, we extend these studies by showing that fibronectin promotes epithelial-mesenchymal transition (EMT) in lung cancer cells. We found that cFN, but not plasma fibronectin or type 1 collagen, induces lung carcinoma cell scattering in vitro, promotes cell migration and invasion of Matrigel and stimulates the expression of the mesenchymal marker α-smooth muscle actin while decreasing the expression of the epithelial marker E-cadherin through PI3-K and Erk pathways. Interestingly, the extra domain A (EDA) within cFN was found to be crucial for this process, as confirmed by testing cells overexpressing EDA or cells exposed to EDA-containing matrices. We found that the integrin α9, but not α5, mediated cFN-induced EMT as silencing integrin α9 neutralized cFN-induced EMT. Overall, our findings show that the EDA domain within cFN induces EMT in lung carcinoma cells through integrin α9-mediated activation of PI3-K and Erk.
Introduction
Lung cancer is the leading cause of cancer death in the USA and worldwide (1) . In most cases, the main cause of death from lung cancer relates to tissue invasion and metastasis by carcinoma cells (2, 3) . One of the first steps in tumor metastasis is the acquisition of cellular motility and invasiveness. During this process, tumor cells partially lose their epithelial markers and gain mesenchymal characteristics, a process termed epithelial-mesenchymal transition (EMT). Although EMT has been recognized as a central feature of normal embryonic development, governing the formation of gastrula, neural crest and the heart, recent studies have revealed that a similar transition occurs during the progression of tumors, and much evidence has accumulated in favor of a role for EMT in tumor metastasis (4, 5) . Thus, defining the factors that promote EMT in the setting of lung carcinoma is likely to lead to the identification of new targets for therapy.
Tumor cell-stroma interactions are becoming increasingly recognized as important determinants of tumor cell fate (2, 6, 7) . Studies in human lung, breast, colon and prostate cancer showed that carcinoma cells are submerged in a microenvironment with fibroblasts and extracellular matrix (ECM) proteins such as fibronectin, collagens, tenascins, proteoglycans, glycosaminoglycans and laminin (2, (6) (7) (8) . As the result of complex interactions between cells and their surrounding stroma, ECMs may affect tumor cell behavior including metastasis (9, 10) . Fibronectin is among the ECM proteins present in tumor tissue, and the fragmentation of pericellular fibronectin with the exposure of cryptic molecular binding sites is considered an early sign of malignancy (11) . Interestingly, the amount of fibronectin messenger RNA in stroma has been found to be 7-13 times higher in carcinoma, which is abnormally high compared with normal tissue (12) . Furthermore, we and others have reported that fibronectin promotes cancer cells proliferation through effects on pro-oncogenic pathways (13) (14) (15) . These and other observations have promoted investigations into fibronectin as a potential target for tumor therapy (16) .
Fibronectin is a high-molecular-weight adhesive glycoprotein that exists in two main forms, as an insoluble glycoprotein dimer present within the ECM or as a soluble disulphide-linked dimer in plasma. Each dimer consists of two nearly identical polypeptide chains and three types of homologous repeating modules termed types I, II and III (17) . Cells may recognize fibronectin through one or more receptors of the integrin family. Eleven different integrin heterodimers have been found to bind to fibronectin, and four of them, α5β1, αvβ3, α4β1 and αIIbβ3, trigger fibronectin fibril formation in vitro (18) . The integrin α5β1 is the best-studied fibronectin-binding integrin, it recognizes the minimal integrin recognition peptide sequence ArgGly-Asp within the fibronectin monomer (19) .
Different isoforms of fibronectin are generated by alternative splicing of combinations of three exons: extra domain A (EDA/ EIIIA), extra domain B (EDB/EIIIB) and connecting segment III (V). The so-called plasma fibronectin (pFN), produced by hepatocytes and abundant in plasma, lacks both the EDA and EDB domains (17, 19) , whereas cellular fibronectin (cFN), produced by fibroblasts, epithelial cells and other cell types, contains the EDA and/or EDB segments. Although the functions of EDA and EDB domains have not been fully elucidated, their ablation leads to embryonic lethality within EDA/EDB double-null animals (20) . Fibronectin containing EDA has been implicated in the regulation of wound healing (21) and is more potent than fibronectin lacking EDA in promoting cell spreading and cell migration irrespective of the presence or absence of EDB (22) . The EDGIHEL sequence within the EDA variant facilitates binding to α4β1 and α9β1 integrins (23, 24) .
In this study, we show that cFN prevents the clustering of lung adenocarcinoma cells resulting in cell scattering (a marker of EMT), promotes cell migration and invasion, and regulates the expression of EMT protein markers through phosphatidylinositol-3-kinase (PI3-K) and Erk pathways. Furthermore, we show that the cFN EDA domain plays an important role in this process by binding to α9 integrin receptors.
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Materials and methods

Cell culture
The human non-small lung carcinoma (NSCLC) cell lines A549 and H1792 were obtained from the American Type Culture Collection and were maintained in Dulbecco's modified Eagle's medium or RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS; Hyclone, Logan, UT) and 50 IU/ml penicillin and 50 IU/ml streptomycin at 37°C in 5% CO 2 , respectively.
Reagents and antibodies
The following reagents were used: cFN (Sigma), collagen (Boehringer Mannheim), pFN (Sigma), transforming growth factor (TGF)-β (BD Biosciences), α9 integrin subunit short interfering RNA (siRNA; Santa Cruz Biotechnology), α5 integrin subunit siRNA (Santa Cruz Biotechnology) and 4′,6-diamidino-2-phenylindole (Santa Cruz Biotechnology). The following antibodies were used: E-cadherin (BD Biosciences), α-smooth muscle actin (α-SMA; Santa Cruz Biotechnology), p-AKT (Cell Signaling), p-Erk (Cell Signaling), total AKT (Cell Signaling), total Erk (Cell Signaling), glyceraldehyde 3-phosphate dehydrogenase (Sigma), goat anti-rabbit horseradish peroxidase secondary antibody (Sigma) and goat anti-mouse horseradish peroxidase secondary antibody (Santa Cruz Biotechnology).
Cell scattering assay A549 and H1792 cells were plated onto eight-well glass chamber slides (3000 cells per well) and cultured with medium containing 1% FBS in the presence or absence of 20 μg/ml of cFN, pFN or type I collagen for the indicated time points. Then, the cells were fixed with methanol for 5 min and washed thoroughly with phosphate-buffered saline (PBS), followed by staining with crystal violet for 20 min. The morphology of the cells was observed and photographs were taken.
Wound healing assay A549 cells (2 × 10 5 ) were plated and grown to 90% confluency in two-well chambers (Falcon BD). Dulbecco's modified Eagle's medium with 10% FBS media was substituted for fresh complete medium containing 1% FBS. Each well was scraped with a sterile 200 μl pipette tip in three separate places, and the cells were grown in the presence or absence of 20 μg/ml cFN, pFN or collagen for 24 h. Then, the wounds were observed and photographs were obtained. The data presented are representative of three independent experiments.
Invasion assay
The invasive ability of H1792 and A549 cells was assayed as follows. Inserts pre-coated with Matrigel™ (Costar) were pre-incubated with complete medium containing 1% FBS in 37°C for 1 h before the cells were plated. Then, the media was replaced with 5 × 10 4 cells in 0.1 ml fresh complete medium containing 1% FBS per well. Media containing 10% FBS was placed in the lower chamber as a chemoattractant. Cells were incubated in the presence or absence of 20 μg/ml cFN, pFN or collagen at 37°C, 5% CO 2 for 24 h. Then, non-migrating cells in the upper chamber of the filters were removed by wiping with cotton swabs. The filters were fixed in methanol followed by staining with crystal violet. The cells migrating to the other side of the filters were quantitated by measuring absorbance at 570 nm wavelength after elution of crystal violet with 33% acetic acid. Data presented represent the mean of at least three independent experiments.
Immunofluorescence analysis A549 and H1792 cells were plated onto eight-well glass chamber slides (3000 cells per well) for immunostaining. Cells were treated with 20 μg/ml cFN for the indicated time points. They were fixed with 10% buffered formalin and double immunofluorescence staining was performed following a previous published protocol (25) . Primary antibodies used were mouse monoclonal IgGs against human E-cadherin (1:3000 dilution) and α-SMA (1:500 dilution). Secondary antibodies used included goat anti-mouse Alexa Fluor-488 (1:200 dilution). 4′,6-Diamidino-2-phenylindole was used to stain the nuclei.
Western blot analysis
The procedure was performed as described previously (26) . Briefly, cells were harvested, lysed and analyzed, and protein concentrations were determined by the Bio-Rad protein assay. Equal amounts of protein (20 μg) from wholecell lysates were solubilized in 2× sodium dodecyl sulfate sample buffer and separated on sodium dodecyl sulfate (8-12%) polyacrylamide gels. Blots were incubated with primary antibodies against E-cadherin (1:3000, 30 min at room temperature), α-SMA (1:500), phospho-Erk (1:500) or phospho-AKT (1:500) overnight at 4°C. After washing, the blots were washed and incubated with a 
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Fibronectin stimulates EMT through integrin α9β1 secondary antibody against rabbit (1:2000) or mouse (1:5000) IgG conjugated to horseradish peroxidase. The blots were washed, transferred to freshly made chemiluminescence solution for 1 min and exposed to X-ray film. In controls, the primary antibodies were omitted or replaced with a control rabbit IgG.
Preparation of fibronectin-derived matrices with different amounts of EDA
Murine lung fibroblasts expressing wild-type EDA, overexpressing EDA or lacking EDA were obtained from Dr E.S.White (University of Michigan). The cells were isolated from wild-type mice and mice lacking EDA as described previously (27, 28) or mice overexpressing EDA (E.S. White et al., unpublished results). The cells were cultured onto plates until they reached confluence. Cells were washed thoroughly with PBS following lyses with the lysis buffer containing 5 mM dithiothreitol, 5 mM urea, 1 mM phenylmethylsulfonyl fluoride, 1% Nonidet P-40, 1% deoxycholate, 1% sodium dodecyl sulfate, 1% Triton X-100, 5 mM ethylenediaminetetraacetic acid, 150 mM NaCl and 50 mM Tris (pH 8.0), then the cell lysis buffer were removed and the plates were washed with PBS. The plates were blocked with 10% bovine serum albumin for 2 h in room temperature and washed with PBS, then stored at 4°C.
Construction of plasmid EDA-Flag and transient transfection
The following primers were designed to amplify the EDA exon regions of the human fibronectin gene: EDA forward primer, 5ʹ CCCAAGCTTAACAT TGATCGCCCTAAAGGA, and reverse primer, 5ʹ CCCGGTACCTGTGGACT GGGTTCCAATCAGG, using RNA isolated from human lung fibroblasts (IMR90). The 290 bp EDA PCR products were separated on a 1% agarose gel and the DNA was extracted and purified using Spin-X (Costar) and Centricep (Princeton Separations) columns. Then, the purified products were ligated into the p3xFLAG-cmv expression vector (Sigma) using HindIII and KpnI restriction sites. The plasmid EDA-Flag was transfected into A549 cells with lipofectamine 2000 when the cells reached 80% confluence. For cell scattering assays, the cells were transfected with integrin α5 or α9 siRNA following the same procedure before and after cFN treatment for 24 h.
siRNA treatment
The integrin α5 siRNA, integrin α9 siRNA and control siRNA were purchased from Santa Cruz Biotechnology. Cells (70% confluence) were transfected with siRNAs using Lipofectamine 2000 reagent (Invitrogen). Briefly, lipofectamine was incubated with serum-free medium for 10 min, mixed with siRNA (100 nM), incubated for 15 min at room temperature before the mixture was diluted with medium and added to cells. After culturing for 40 h, cells were washed, resuspended in fresh media, treated with or without nicotine for an additional 24 h and analyzed by western blot and cell viability assay.
Statistical analysis
All experiments were repeated a minimum of three times. All data were expressed as means ± SD. The data presented in some figures are from a representative experiment, which was qualitatively similar in the replicate experiments. Statistical significance was determined with Student's t-test (twotailed) comparison between two groups of data sets. Figure 1A and C) . cFN induced the elongation of cells, which took a fibroblast-like shape. The same effects were also found in an additional cell line, H1792 ( Figure 1B and C) . As TGF-β is a well-known inducer of EMT in many carcinoma cells, it was used in this assay as a positive control. Like cFN, TGF-β prevented A549 cell clustering, which is consistent with previous reports (Figure 1 ).
Results
cFN prevents lung adenocarcinoma cell clustering in vitro
In the absence of cFN stimulation, colonies grew in clusters, which increased with time. To quantify our results, colonies containing >10 cells were counted after 72 and 96 h of treatment. We found that 25.5 ± 1.04 and 36.7 ± 4.23 colonies were formed in untreated A549 cells after 72 and 96 h, respectively, whereas only 0.5 ± 0.5 and 1.0 ± 1.0 colonies formed in cFN-treated cells at the same time points ( Figure 1C ). Similar observations were made for H1792 ( Figure 1C ).
In contrast with the effects of cFN, many colonies were formed by cells treated with pFN or type 1 collagen (20 μg/ml; Figure 1D ). These results show that cFN, but not collagen or pFN, results in cell scattering in vitro. 
cFN promotes lung adenocarcinoma cell migration and invasion
To examine whether cFN promotes cell migration, A549 cells were grown to 90% confluence and submitted to an in vitro 'wound healing assay'. After 24 h of exposure to cFN, significant migration was noted with 75% obliteration of the wounded area, but no obvious effects were observed for type 1 collagen and pFN (Figure 2A ). To determine whether cFN could promote lung adenocarcinoma cell invasion, an in vitro invasion assay was performed with A549 and H1792 cells. cFN was found to significantly increase cell invasion when compared with collagen and pFN ( Figure 2B and C) . Thus, cFN increases both migration and invasion of lung carcinoma cells.
cFN modulates the expression of epithelial and mesenchymal protein markers
A critical feature of EMT is the downregulation of epithelial markers like E-cadherin, a cell adhesion molecule present in the plasma membrane of most normal epithelial cells. Therefore, we tested the effect of cFN on E-cadherin expression. In A549 cells, E-cadherin staining (red) was decreased after 72 h of cFN treatment (Supplementary material, available at Carcinogenesis Online). In contrast, staining for the classic mesenchymal marker, α-SMA, was increased (green; Supplementary material, available at Carcinogenesis Online). These results were confirmed by western blot as shown in Figure 3 .
Phosphatidylinositol-3-kinase/protein kinase B and Erk are involved in cFN-induced EMT
We demonstrated previously that fibronectin promotes cell proliferation through increased phosphorylation of the PI3-K downstream signal AKT and of Erk in NSCLC cells (13, 14, 29) . Thus, we examined whether these pathways mediated the effect of cFN. We found that the AKT inhibitor, wortmannin, and the Erk inhibitor, PD98059, reduced the effect of cFN on E-cadherin expression, whereas the inhibitor of protein kinase A had no effect ( Figure 4A ). Moreover, these two inhibitors also significantly diminished cFN-induced cell scattering ( Figure 4B ).
To further test the effect of cFN on these kinases, we evaluated if cFN induces the phosphorylation of AKT and Erk starting at 15 min ( Figure 4C) ; the inhibitor of AKT had no effect on cFN-induced Erk activation ( Figure 4D) . Similarly, the inhibitor of Erk had no effect on AKT activation ( Figure 4D ). Therefore, these kinases appear to influence E-cadherin expression via distinct pathways.
The EDA domain in cFN is responsible for cFN-induced EMT
To test the role of the EDA domain in cFN-induced EMT, the cells were cultured in plates pre-coated with three types of matrices: (i) matrices derived from fibroblasts expressing wild-type fibronectin EDA, (ii) matrices derived from fibroblasts expressing fibronectin deficient in EDA (EDA−/− ECM) and (iii) matrices derived from fibroblasts overexpressing EDA (EDA+/+ ECM). Few loose and small colonies companied by surrounding scattered cells were found with EDA+/+ ECM, whereas an increased number of compact colonies was observed in EDA−/− ECM ( Figure 5A ). 
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Of note, changes noted in cells cultured on EDA+/+ ECM were associated with increased phosphorylation of AKT and Erk ( Figure 5A ).
We then tested the effect of EDA overexpression on cFN-induced EMT using cells transfected with a plasmid containing EDA-Flag. The strategy for the generation of cloning the EDA vector is shown in Figure 5B . The effectiveness of transfection of increasing doses of the EDA vector into NSCLC cells was examined by determining EDAFlag protein expression ( Figure 5C ). Note that the non-vector and control vector had no EDA-Flag protein ( Figure 5C ). Consistent with a role for EDA in EMT, we showed that exogenous expression of EDA decreased E-cadherin, but it increased α-SMA expression in A549 cells ( Figure 5C ). These effects were associated with phosphorylation of Erk and Akt as determined by western blot analysis ( Figure 5A ).
α9β1 Integrin mediates cFN-induced EMT
Having established that the EDA domain of cFN stimulates EMT through the phosphorylation of AKT and Erk, we set out to investigate the receptor mediating these effects. Integrin receptors are required for fibronectin to bind to cells and stimulate signal transduction. Besides the classic fibronectin receptor α5β1, many integrins are able to bind fibronectin. To assess which integrin mediates cFN-induced EMT, we examined the effects of silencing of the α5 and α9 integrin subunits on A549 cells. We found that silencing of α9, but not α5 integrin, significantly diminished cFN-induced cell scattering, allowing for the formation of more colonies ( Figure 6A ). Silencing of α9 also blocked cFN-induced cell migration and invasion ( Figure 6B and C) , and abrogated cFN-induced phosphorylation of AKT and Erk ( Figure 6D ). These data suggest that the integrin α9 mediates cFN-induced EMT.
Discussion
Since the original description of EMT in 1985, when fibroblast culture supernatant was shown to contain a 'scatter activity' for epithelial Madin-Darby canine kidney cells (30) , several factors have been identified to trigger EMT including hypoxia (31) and growth factors such as TGF-β, hepatocyte growth factor/scatter factor, fibroblast growth factor, epidermal growth factor and platelet-derived growth factor (32) . It is noticeable that these factors act extracellularly and exert their effects on cells through cell surface receptors. This highlights the importance of the microenvironment in regulating tumor cell behavior.
Another factor capable of promoting EMT is the stroma. The proliferation of fibroblasts, accompanied by an accumulation of connective tissue, is a typical feature in many solid tumors (7, 11, 33) . Also, factors associated with increased incidence of lung cancer (e.g. nicotine and alcohol exposure) promote the deposit of ECM in lung (34, 35) . Hypoxia, considered a promoter of tumor progression, also stimulates matrix deposition (36) . Thus, there appears to be an association between carcinoma development and tissue fibrosis. One ECM component found to be increased in the setting of lung cancer is fibronectin. In this work, we demonstrate that cFN not only stimulates lung cancer cell growth as we reported previously, but it also promotes EMT through the repression of epithelial cell markers and the induction of a mesenchymal phenotype. This leads to enhanced cell migration and invasion in adenocarcinoma cells. 
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However, not all fibronectins are the same. Soluble pFN, for example, did not promote EMT, whereas cFN did. cFN is different from pFN in that it contains the EDA and/or EDB domains. The importance of EDA in vivo was shown in studies demonstrating abnormal wound healing in mice lacking the EDA domain, and increased differentiation of fibroblasts into myofibroblasts in vivo with induced expression of α-SMA (37). Compared with EDA, EDB is lost in almost all cell types (38) , but it is expressed in many kinds of tumor cells, such as lung tumors and hepatocellular carcinoma (39) . Recently, EDB was targeted for the development of antibody-based cancer treatments based on its growth promotion effects on tumor cells (40) . To address whether or not the EDA domain within cFN induces EMT, matrices derived from fibroblasts producing different concentrations of EDA were used. We found that matrices containing excess amounts of EDA induced cell scattering and downregulation of E-cadherin; overexpression of EDA had the same effect. Thus, EDA may induce EMT in lung cancer cells.
In exploring the signaling pathways involved in EMT, it was reported that inhibition of AKT activity leads to mesenchymal-toepithelial transition with restoring E-cadherin expression in oral squamous cell carcinoma cells (41) . Previously, we showed that fibronectin stimulates lung cancer cell proliferation through induction of phosphorylation of molecules involved in the PI3-K/AKT and Erk pathways (42) . This study suggests that AKT and Erk are also involved in cFN-induced EMT. No cross interaction was found between AKT, and Erk was detected suggesting that cFN induces EMT through AKT and Erk pathways that appear to be independent from each other.
Finally, we examined the identity of the integrin receptors mediating cFN-induced EMT. Integrins are heterodimeric transmembrane proteins composed of α and β subunits that mediate cell-cell and cellmatrix interactions (43) . Once activated, integrins transmit signals that connect cell surface stimulation to the cytoskeleton and the transcription machinery. Importantly, integrins play different roles in cellular processes related to growth, survival, apoptosis and differentiation. The α5β1 integrin is considered the major receptor for fibronectin, and it recognizes the Arg-Gly-Asp motif in its ligand (44) . Our previous studies showed that α5β1 integrin contributes to cell proliferation through the activation of multiple oncogenic pathways (45) . Another fibronectin integrin, α9β1 is a receptor for vascular cell adhesion molecule 1, is expressed in many mammalian tissues and can mediate accelerated cell migration (46, 47) . The integrin α9β1 has been found to be upregulated in small cell lung cancers (48) . Others have shown that the EDA portion of cFN binds the α9β1 (24). EDA-α9β1 interactions were reported to be crucial for efficient and proper re-epithelialization during cutaneous wound healing (47, 49) . Considering the above, we tested the roles of both the α5β1 and α9β1 in cFN-induced EMT. Knockdown of α9 integrin, but not of α5, blocked the response of cells to cFN, suggesting that α9 integrin mediates cFN-induced EMT through interactions with EDA.
In summary, this study showed that EDA within cFN stimulates EMT in human lung carcinoma cells through binding the α9β1 integrin. In turn, this leads to phosphorylation of AKT and Erk followed by downregulation of E-cadherin and upregulation of α-SMA. This prevents cell clustering and enhances cell migration and invasion. Together, our observations reveal a novel molecular mechanism by which cFN regulates human lung carcinoma cell behavior and provides further evidence in support of the role of fibronectin in lung carcinoma biology.
